Press release 📈 Stocks 🌍 Sweden

Sobi and Ionis Secure EU Approval for Tryngolza in sHTG Patients

Sobi and Ionis receive EU approval for Tryngolza to treat severe hypertriglyceridaemia, expanding the drug's reach to 700,000 patients and demonstrating significant reductions in triglyceride levels and pancreatitis risk.

🕐 1 min read

2 assets impacted (Stocks). Net bias: 2 Bullish, 0 Bearish, 0 Neutral. Strongest signal: SOBI ↑ 6/10 (80% confidence).

📊 Affected Assets (2)

SOBI
Bullish 🤖 80%
📅 Short-term 🌍 SE · Explicit

The European Commission approved Tryngolza (olezarsen) on Nov 17, 2026 for severe hypertriglyceridaemia, expanding the label from familial chylomicronemia syndrome to roughly 700,000 people with TG ≥880 mg/dL in the EU5. As holder of exclusive ex-US commercialisation rights (excluding Canada and China), Sobi gains a materially larger addressable market with Phase 3 data showing up to 73% triglyceride reduction and 83% fewer pancreatitis events.

Catalysts
  • ▲ EC approval of Tryngolza for sHTG announced November 17, 2026
  • ▲ Label expansion from FCS to ~700,000 EU5 patients with TG ≥880 mg/dL
Risk Factors
  • ▼ Commercial launch and reimbursement in EU member states still to be executed
  • ▼ Competition from existing lipid-lowering therapies in sHTG
IONS
Bullish 🤖 70%
📅 Short-term 🌍 US · Explicit

Ionis sponsored the pivotal Phase 3 CORE and CORE2 trials and developed olezarsen; the CEO calls Sobi a long-standing partner. The EU regulatory approval validates the drug's efficacy (73% triglyceride reduction) and expands the ex-US market, supporting royalty/licence economics even though Ionis itself commercialises only in the US.

Catalysts
  • ▲ EC approval of olezarsen for sHTG on November 17, 2026
  • ▲ Phase 3 CORE/CORE2 data supporting approval with statistically significant results (p<0.001)
Risk Factors
  • ▼ Ionis commercialises Tryngolza directly only in the US; ex-US upside flows mainly through partner Sobi
  • ▼ No financial terms of the licence agreement disclosed in the announcement

🧭 Full analysis of these assets

🎯 Key Takeaways

  • The European Commission approved Tryngolza for adults with sHTG (triglyceride levels ≥880 mg/dL) on November 17, 2026.
  • Phase 3 CORE and CORE2 trials showed a 73% reduction in triglyceride levels at 6 months and an 83% reduction in acute pancreatitis events.
  • The approval expands the addressable market to approximately 700,000 people in the EU5.
  • Sobi holds exclusive commercialisation rights for Tryngolza in the EU, while Ionis developed the drug and holds US rights.

📝 Executive Summary

The European Commission has approved Sobi's Tryngolza (olezarsen) for treating adults with severe hypertriglyceridaemia (sHTG) with triglyceride levels ≥880 mg/dL. This label expansion targets approximately 700,000 patients in the EU5, following Phase 3 data showing a 73% reduction in triglycerides and an 83% decrease in acute pancreatitis events.

❓ FAQ

SOBI · What did the EU approve and for whom?

The European Commission approved Tryngolza (olezarsen) as an adjunct to diet and other lipid-lowering therapies for adults with severe hypertriglyceridaemia (fasting triglycerides ≥880 mg/dL), the first and only RNA-targeted therapy authorised in the EU for this population.

SOBI · Why does this matter for Sobi's business?

Sobi holds exclusive rights to commercialise Tryngolza outside the US (except Canada and China). The approval expands the label beyond familial chylomicronemia syndrome to an estimated 700,000 people in the EU5 with triglyceride levels ≥880 mg/dL, significantly widening the patient population Sobi can serve.

IONS · What is Ionis's role in this EU approval?

Ionis discovered and developed olezarsen and sponsored the Phase 3 CORE and CORE2 studies; Sobi has exclusive rights to commercialise Tryngolza in ex-US geographies except Canada and China.